Introduction
Glioblastoma multiforme (GBM) is classified as a Grade IV astrocytoma by the World Health Organization (WHO) and is the most malignant form of adult brain tumor. GBMs are highly proliferative, invasive and largely radio-resistant. These properties contribute to high mortality rates, poor prognosis and little chance for long-term survival. Primary GBMs occur de novo and 50-60% of the cases have epidermal growth factor receptor (EGFR) amplification or overexpression (Maher et al., 2001; Thomas et al., 2003) . In addition to EGFR overexpression, many GBMs demonstrate overexpression of protein kinase C (PKC) isozymes and proteins involved in the PI3K (phosphatidylinositol 3 0 -kinase)/AKT/mTOR (mammalian target of rapamycin) signaling module (Feldkamp et al., 1997; Choe et al., 2003; Rajasekhar et al., 2003) . As the mTOR pathway is activated in GBM tumor samples, rapamycin and its analogs have been tested as chemotherapeutic agents in the treatment of glioblastoma. Although rapamycin and its analogs have demonstrated potential as chemotherapeutic agents in the treatment of several cancers including GBMs, recent studies suggest certain populations of cancer cells are not susceptible to rapamycin inhibition of cell proliferation (Huang and Houghton, 2001; Dilling et al., 2002; Chen et al., 2003; Gera et al., 2004; Noh et al., 2004; Galanis et al., 2005) .
PKCs are a family of phospholipid-dependent enzymes involved in signal-transduction pathways associated with cell growth, gene expression and cell migration (Nishizuka, 1984 (Nishizuka, , 1988 Stolovich et al., 2002) . The PKC family members are grouped into three major classes, classical (cPKC), novel (nPKC) and atypical (aPKC) PKCs. The cPKCs (a, bI, bII, g ) are activated by diacylglycerols (DAG) and phorbol esters only in the presence of calcium. The nPKCs (d, e, Z, y) are regulated by DAG and phorbol esters, but their activation does not require calcium. The aPKCs are not activated by DAG or phorbol esters (Parker and Murray-Rust, 2004) . PKC isozymes are overexpressed in human glioma cell lines and human glioblastoma tumor specimens (Feldkamp et al., 1997) . Phorbol 12-myristate 13-acetate (PMA) is a phorbol ester that induces classical and novel PKC membrane translocation and activation (Nishizuka, 1984) . We have shown that PKC-Z-expressing cells demonstrate increased rates of PMA-induced cell proliferation and are resistant to radiotherapy (Hussaini et al., 2000 (Hussaini et al., , 2002 . Activation of PKC isozymes, including PKC-Z, by PMA and other agents promote activation of the PI3K/AKT/mTOR pathway in several cell types, including glioblastomas (Aeder et al., 2004) . Although the regulatory functions of many PKC isozymes in controlling cell growth and proliferation have been established in other cells, the function of PKC isozymes in glioblastoma is not well understood.
The PI3K/AKT signaling cascade is frequently activated in malignant astrocytic tumors (Schlegel et al., 2002a, b) . GBM cells that either express an inactive mutant of phosphatase and tensin homolog deleted on chromosome 10 (PTEN) or do not express PTEN demonstrate constitutive activation of AKT, mTOR and G1-associated cyclin-dependent kinases (Steck et al., 1999; Choe et al., 2003) . Activation of the PI3K/AKT signal cascade results in the activation of mTOR, a serine-threonine kinase in the family of phosphoinositide kinase-related kinases (Hara et al., 1997; Schmelzle and Hall, 2000; Gingras et al., 2001; Jacinto and Hall, 2003) . mTOR activation regulates mRNA translation by phosphorylating p70S6K and 4E binding protein (4EBP-1, also known as PHAS-I). Previous studies have proven that phosphorylation and activation of 4EBP-1 leads to increased translation initiation (Pause et al., 1994; Lawrence and Abraham, 1997) .
Regulation of p70S6K activation is dependent on the phosphorylation of several serine/threonine sites (T389, S411, S418, S424 and T421). Specifically, T389 phosphorylation by mTOR primes subsequent phosphorylation sites and permits complete activation of p70S6K Dennis et al., 1996; Burnett et al., 1998) . The kinase activity of mTOR and the phosphorylation of p70S6K and 4EBP-1 are inhibited by rapamycin (Jefferies et al., 1997) . Rapamycin, a bacterial macrolide with high specificity for mTOR, has been used clinically to prevent organ transplant rejection and restenosis (Chung et al., 1992; Han et al., 1995; Aspeslet and Yatscoff, 2000; Rodriguez et al., 2003; Levy et al., 2004) . Rapamycin is currently in clinical trials as a chemotherapeutic agent in several cancers including recurrent brain tumors (Newton, 2004; Xu et al., 2004) .
Rapamycin prevents glioblastoma cell proliferation in vitro and xenograft cell growth in vivo (Yu et al., 2001) . Rapamycin also increases the effectiveness of radiation in U-87MG glioblastoma cells (Eshleman et al., 2002) . However, certain breast cancer cell lines are resistant to rapamycin, whereas others are susceptible to rapamycin (Noh et al., 2004) . This resistance has been correlated with the activity level of AKT and p70S6K. Expression of the cell cycle regulatory proteins c-myc and cyclin D1 has also been linked to rapamycin insensitivity in breast cancer and brain tumor cells (Gera et al., 2004; Noh et al., 2004) .
In this study, we investigated the efficacy of rapamycin in two glioblastoma cells including cells expressing PKC-Z (U-251MG) and cells deficient in PKC-Z (U-1242MG). Additionally, we used U-251MG cells infected with a dominant-negative (kinase dead) form of PKC-Z (U-251kr) and silenced PKC-Z expression using antisense oligonucleotides. We show that glioblastoma cells expressing PKC-Z were resistant to rapamycin treatment after stimulating the cells with serum and PMA simultaneously. However, cells lacking PKC-Z activity were susceptible to rapamycin-induced inhibition of cell proliferation. Using PKC-Z antisense constructs, we demonstrated a PKC-Z-mediated regulation of p70S6K phosphorylation and conclude that PKC-Z and p70S6K are involved in rapamycin-insensitive cell proliferation in glioblastoma cells.
Results

Expression and activation of PKC-Z reduces efficacy of rapamycin
We determined the rate of GBM cell proliferation in vitro by measuring the amount of 3 H-thymidine incorporated into U-251MG (PKC-Z-expressing), U-1242 (PKC-Z-deficient) and U-251kr (PKC-Z kinase dead) cells, following rapamycin treatment. Rapamycin reduced the relative rate of 3 H-thymidine incorporation in serum-treated U-251MG cells to basal levels. However, when U-251MG cells were treated with a combination of PMA (100 nM) and serum (10%), the rate of cell proliferation remained elevated (2.5-fold) after rapamycin (10 nM) treatment in comparison with serumstarved control cells ( Figure 1a ). Serum-stimulated U-1242MG cells demonstrated a fourfold increase in cell proliferation when compared with control serumstarved U-1242MG cells (Figure 1b ). Rapamycin decreased cell proliferation of U-1242MG cells over 50% ( Figure 1b ). Previously, we have shown that PMA stimulation of U-1242MG resulted in a significant decrease in cell proliferation, owing to PKC-Z deficiency (Hussaini et al., 2000) . Stimulation of U-1242MG cells with PMA and serum after rapamycin (10 nM) treatment did not promote cell proliferation (Figure 1b ). Rapamycin (10 nM) treatment of U-251kr cells resulted in a decrease in cell proliferation. Like U-1242MG cells, U-251kr cells stimulated with PMA and serum following rapamycin treatment demonstrated a decrease in 3 H-thymidine incorporation ( Figure 1c ). These data suggest that PMA-induced activation of PKC-Z in the presence of serum enables PKC-Z-expressing cells to maintain their capacity to proliferate following rapamycin treatment.
PKC-Z regulates p70S6K phosphorylation in response to PMA To investigate the intracellular mechanisms controlling rapamycin sensitivity in these glioblastoma cell lines, we determined the phosphorylation states of p70S6K in response to rapamycin treatment. All cell lines were serum starved for 18 h to reduce basal phosphorylation levels, and then incubated in the presence of rapamycin (10 nM) for 4 h before stimulation with PMA (100 nM) and/or 10% serum. In U-251MG cells not treated with rapamycin, p70S6K phosphorylation (Thr389) was observed in cells stimulated with serum and/or PMA ( Figure 2a ). U-251MG cells exposed to rapamycin, but not stimulated with PMA, exhibited no p70S6K phosphorylation ( Figure 2a ). However, U-251MG cells treated with rapamycin and then stimulated with PMA demonstrated p70S6K phosphorylation ( Figure 2a ). Sustained phosphorylation of p70S6K in cells stimulated with a combination of PMA and serum correlates with the continued cell proliferation of these cells ( Figure 1a) . p70S6K was phosphorylated in U-1242MG and U-251kr cells stimulated with PMA and/or serum and not exposed to rapamycin (Figure 2b ). Following rapamycin treatment, p70S6K phosphorylation was attenuated in U-1242MG and U-251kr cells regardless of mitogenic stimulation (Figure 2b and c, arrows indicate hyper-phosphorylated form of p70S6K). These data correlate with rapamycin-mediated inhibition of cell proliferation in U-1242MG and U-251kr cells (Figure 1b and c) . As U-1242MG and U-251kr cells are able to phosphorylate p70S6K and proliferate in the absence of rapamycin, the lack of PKC-Z does not result in global interference of PMA-activated pathways, but appears specific to PKC-Z-mediated induction of rapamycin-insensitive proliferation in glioblastoma.
We next assayed the phosphorylation states of downstream targets of p70S6K, S6 (ribosomal protein S6) and eEF2K (eucaryotic elongation factor 2 kinase), in U-251MG and U-251kr cells after rapamycin treatment to determine whether Thr389 phosphorylation coincides with p70S6K activity. Rapamycin attenuated S6 phosphorylation (Ser235/36) in U-251MG and U-251kr cells that were not treated with PMA. However, U-251MG cells treated with PMA displayed S6 phosphorylation and U-251kr cells showed minimal phosphorylation (Figure 3a) . eEF2k (ser 366) phosphorylation was increased after rapamycin treatment in U-251MG cells following PMA treatment, but was decreased in U-251kr cells. These data indicate that the combination of PMA and serum mediate rapamycininsensitive p70S6K kinase activity in glioma cells expressing PKC-Z (Figure 3b ).
PKC-Z antisense knockdown attenuates p70S6K phosphorylation and glioblastoma cell proliferation To further investigate the regulation of rapamycininsensitive glioma proliferation, we knocked down the expression of PKC-Z by antisense in U-251MG, PKC-Zexpressing cells. First, we established a U-251MG clone (JCI-a3) with lower levels of PKC-Z expression (Figure 4a ). We next treated the cells with rapamycin in the presence of PMA and/or serum and analysed the phosphorylation states of p70S6K (Thr389) and S6 (Ser235/36). PKC-Z expression levels in these cells did not affect the basal phosphorylation of either protein (Figure 4b ). Following rapamycin treatment, p70S6K and S6 phosphorylation was significantly decreased in the JCI-a3 clone, but not in the JCI-a0, empty vector, transfected cells (Figure 4b ). We also assayed the proliferative capacity of these cell lines. In comparison to the JCI-a0 cell line, JCI-a3 clone (antisense PKC-Z) did not proliferate as robustly and was not resistant to rapamycin after concurrent stimulation with PMA and serum (Figure 4c) . Moreover, the proliferative pattern of JCI-a3 clone is similar to that of U-1242MG and U-251kr cells. As antisense knockdown of PKC-Z confers rapamycin sensitivity to these cells, this further suggests that PKC-Z expression is involved in promoting rapamycin-insensitive cell proliferation in these cells.
siRNA-mediated gene silencing of p70S6K in U-251MG cells Thus far, we have shown that PKC-Z-expressing glioblastoma cell lines proliferate and activate p70S6K in the presence of rapamycin. As changes in Thr389 phosphorylation of p70S6K correlate with the proliferative capacity of the glioblastoma cell lines, we silenced p70S6K with small interfering RNA (siRNA). U-251MG cells transfected with p70S6K siRNA (200 Figure 3 PKC-Z regulates rapamycin-insensitive S6 and eEF2k phosphorylation. U-251MG and U-251kr were exposed to rapamycin 10 nM for 4 h, then stimulated with 10% serum and/or PMA 100 nM for 1 h before cell lysing. The cell lysate was used to detect the phosphorylation state of (a) S6 and (b) eEF2k. In (b), total S6 was used as a loading control, see (a). and 400 nM) demonstrated a reduction in total p70S6K protein level and its phosphorylated form (Figure 5a ). The reduction in p70S6K protein was not owing to a decrease in overall protein levels or nonspecific protein knockdown, as loading controls were equal in all lysates and the protein level of mTOR was not reduced (Figure 5a ). Using 400 nM of p70S6K siRNA, we were able to inhibit serum-stimulated cell proliferation in U-251MG cells (Figure 5b) . In U-251MG cells stimulated with a combination of serum and PMA, the rate of cell proliferation was reduced by 50%, in comparison to cells transfected with control siRNA (Figure 5b) . Furthermore, cells treated with p70S6K siRNA spread less than cells treated with control siRNA (data not shown). This difference in cell morphology did not result in an increased percentage of cells in sub-G 0 (scramble siRNA 2.2% and p70S6K siRNA 2.4%). These data indicate p70S6K expression and activity in addition to PKC-Z is involved in sustaining the rapamycin-resistant proliferation in these glioblastoma cell lines.
p70S6K and PKC-Z interact in human glioblastoma cells To understand the mechanism by which PKC-Z regulates p70S6K, we investigated whether PKC-Z and p70S6K could interact. PKC-Z interacts with p70S6K in U-251MG cells, suggesting that p70S6K activity is regulated by an interaction between PKC-Z and p70S6K (Figure 6a) . In Figure 6b , we confirmed the expression of PKC-Z in U-251MG cell lysates by Western blot analysis.
Discussion
Previous reports have established rapamycin and its analogs as potential chemotherapeutic agents in the treatment of glioblastoma and other cancers (Geoerger et al., 2001; Neshat et al., 2001; Dutcher, 2004) . Preclinical studies have demonstrated that certain breast and prostate cancers as well as glioblastomas are extremely sensitive to rapamycin (Neshat et al., 2001 ). However, recent studies in breast and ovarian cancer cell lines suggest rapamycin-insensitive cell lines exist (Noh et al., 2004) .
The molecular analysis of rapamycin resistance has focused on major proteins involved in the AKT/mTOR signaling cascade and several cell cycle proteins (Dilling et al., 2002; Gera et al., 2004) . None of these studies examined whether PKC isozymes could regulate rapamycin resistance. Expression of PKC isozymes mediates chemoresistance in leukemia and breast cancer (Jiffar et al., 2004; Schondorf et al., 2004) . Moreover, PKC-Z expression is increased in glioblastoma cells, and PKC-Z expression in human astrocytoma cells has been shown to promote cell proliferation and resistance to irradiation-induced apoptosis (Hussaini et al., 2000 (Hussaini et al., , 2002 .
We have found that PKC-Z-expressing glioblastoma cells are insensitive to the antiproliferative effects of rapamycin when stimulated concurrently with PMA, a potent activator of PKCs and serum. Concurrent treatment of PKC-Z-expressing cells with PMA and serum also resulted in sustained kinase activity and phosphorylation of p70S6K on Thr389 after exposure to rapamycin for 4 h. Glioblastoma cells lacking PKC-Z expression and cells expressing kinase dead PKC-Z were sensitive to rapamycin, and PMA treatment of these cells resulted in decreased cell proliferation and inhibition of Thr389 phosphorylation on p70S6K. PKC-Z activity correlated with S6 phosphorylation, suggesting that ribosome biogenesis continues in rapamycin-insensitive GBM cells. We extended these findings with PKC-Z gene silencing. Reduction of PKC-Z levels in U-251MG cells reversed the rapamycin-insensitive cell proliferation observed previously. These results demonstrate a correlation between PKC-Z expression and rapamycin insensitivity in the cell lines tested.
Our present study adds PKC-Z to the list of proteins, including AKT and phospholipase D (PLD), that when activated in certain cell types are associated with rapamycin resistance. PLD activity may further explain how PKC-Z confers rapamycin resistance in human breast cancer cells, as PKCs are known activators of PLD (Chen et al., 2003) . A similar mechanism, albeit indirect, may also participate in the rapamycin resistance described in our studies. It is believed that phosphatidic acid (PA) and rapamycin compete for binding sites on mTOR, and this mechanism accounts for PA-mediated rapamycin resistance in breast cancer cells (Fang et al., 2001) . As PA is known to activate PKC isozymes, it is possible that PKC activation could lead to PLD production of PA and phosphatidylcholine that, in turn, would activate PKC isozymes (Lang et al., 1995) . Such a mechanism could result in a positive feedback loop that would maintain PKC and PA activation, bypassing rapamycin-mediated inhibition of cell proliferation. Recently, Rictor, an mTOR binding protein has also been conclusively shown to mediate rapamycin insensitive signaling (Sarbassov et al., 2004) . Unpublished observations in our laboratory demonstrate equal amounts of Rictor expression in PKC-Zexpressing and PKC-Z-deficient cells.
siRNA-mediated gene silencing knockdown of p70S6K significantly reduced U-251MG cell proliferation. Although siRNA gene silencing attenuated the rate of cell proliferation and p70S6K phosphorylation of Thr389, it did not completely abolish cell proliferation. The continued proliferation of U-251MG cells transfected with p70S6K siRNA suggests that this is not the only mechanism by which glioblastoma can control cell proliferation. It is plausible that the residual cell proliferation could be explained by activation of the extracellular signal-regulated kinase (ERK) signaling pathway, which is capable of regulating glioblastoma cell proliferation in response to PMA and serum (Hussaini et al., 2000) .
Our studies indicate that PKC-Z can regulate the phosphorylation and kinase activity of p70S6K in human glioblastoma cell lines, resulting in cell proliferation and resistance to rapamycin following concomitant PKC activation and serum stimulation (Figure 7) . Phosphorylation of p70S6K is regulated by both mTOR and PKC-Z as inhibition of either of these proteins alone does not abolish Thr389 phosphorylation on p70S6K, whereas removal of both kinases with a combination of molecular and pharmacological inhibitors ablates Thr389 phosphorylation and proliferation. Glioblastoma cells expressing PKC-Z lose their sensitivity to rapamycin-mediated inhibition of cell proliferation. This insensitivity to rapamycin can be overcome by either decreasing PKC-Z expression or abolishing PKC-Z kinase activity. Taken together, our present data along with previous findings demonstrate a mitogenic mechanism that confers rapamycin-insensitivity in human glioblastoma cells.
Materials and methods
Reagents
Bisindolymaleimide, rapamycin and PMA were purchased from Calbiochem (San Diego, CA, USA). Antibodies against Cell culture U-251MG and U-1242MG cell lines were generously supplied by Dr DD Bigner (Duke University) and Dr AJ Yates (Ohio State University), respectively. Both cell lines were isolated from characterized glioblastoma tumors and these cell lines have been described extensively. Stably infected U-251kr cells have been described previously (Aeder et al., 2004) . PKC-Z antisense clones have been described previously (Hussaini et al., 2000) . Cells were cultured in minimal essential medium-a (MEM-a) supplemented with 10% fetal bovine serum (FBS) (Hyclone, Logan, UT, USA).
Western blot analysis
To detect expression and phosphorylation levels of proteins, the cells were first washed in 1 Â Dulbecco's phosphatebuffered saline (DPBS) containing 2 mg/ml of sodium orthovanadate (Sigma, St Louis, MO, USA). Proteins were then extracted from the cells with 1% Triton X-100 and resolved on an 8% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) gel as described previously (Hussaini et al., 2000) . All Western blots are representative of three independent experiments.
siRNA gene silencing siRNA oligonucleotides were transiently transfected using Amaxa nucleofection technology (Amaxa, Gaithersburg, MD, USA) (Maasho et al., 2004) . After nucleofection, cells were cultured for 36 h in serum-containing media and then cultured for 12 h in serum-free media before 1 h stimulation with PMA (100 nM) and serum (10% FBS) before lysing. Cells used to determine cell proliferation were cultured for 30 h postnucleofection and then stimulated with PMA (100 nM) and/ or serum (10% FBS) for 12 h. At this time, the cells were then pulsed with 3 H-thymidine for 6 h.
Immunoprecipitation of PKC-Z Cells were grown to 70% confluency and then serum-starved overnight. After starvation, the cells were treated with rapamycin for 4 h before stimulation with PMA (100 nM) and serum (10% FBS) for 1 h. Cells were rinsed with cold PBS and extracted as described above. After normalization of supernatants derived from treated and untreated cells for protein concentration, 1 mg of each lysate was incubated with anti-p70S6K (Sc-230, Santa Cruz Biotechnology, Santa Cruz, CA, USA) overnight at 41C. Immune complexes were collected with protein A beads and washed five times with immunoprecipitation buffer containing 50 mM sodium acetate buffer, pH 5.0, 500 mM NaCl, 0.1% SDS and 1% Nonidet P-40. The resulting immunoprecipitate was then subjected to 8% SDS-PAGE and transferred onto nitrocellulose membranes, followed by Western blot analysis with anti-PKC-Z antibody.
H-thymidine incorporation
The relative rate of cell proliferation was determined by 3 H-thymidine incorporation into actively proliferating cells before fixing with trichloroacetic acid (TCA) as described previously (Hussaini et al., 2000) . 3 H-thymidine incorporation was measured with a Beckman Liquid scintillation counter.
Statistical analysis
Experiments examining 3 H-thymidine incorporation were averaged and the averages and s.e.m. from three individual experiments were analysed for statistical significance using a one-tailed analysis of variance and the Student-NewmanKuels test.
